Hs-cTnT as a risk factor for the primary end point ( cardiovascular death , nonfatal myocardial infarction , and nonfatal stroke ; n = 356 ) , as well as all-cause mortality ( n = 366 ) , cardiovascular mortality ( n = 299 ) , and the composite of cardiovascular mortality and hospitalization from worsening of HF ( n = 465 ) , was investigated in 1245 patients ( 60 years ; New York Heart Association [ NYHA ] class II-IV , ischemic systolic HF ) randomly assigned to 10 mg rosuvastatin or placebo .